DISCLAIMER

Our systems have detected that you are using a computer with an IP address located in the USA.
If you are currently not located in the USA, please click “Continue” in order to access our Website.

Local restrictions - provision of cross-border services

Swissquote Bank Ltd (“Swissquote”) is a bank licensed in Switzerland under the supervision of the Swiss Financial Market Supervisory Authority (FINMA). Swissquote is not authorized as a bank or broker by any US authority (such as the CFTC or SEC) neither is it authorized to disseminate offering and solicitation materials for offshore sales of securities and investment services, to make financial promotion or conduct investment or banking activity in the USA whatsoever.

This website may however contain information about services and products that may be considered by US authorities as an invitation or inducement to engage in investment activity having an effect in the USA.

By clicking “Continue”, you confirm that you have read and understood this legal information and that you access the website on your own initiative and without any solicitation from Swissquote.

Research Market strategy
by Swissquote Analysts
В понедельник утром акции на итальянском фондовом рынке повсеместно росли, особенно в финансовом секторе, тогда как доходность казначейских облигаций упала до 1-месячного минимума. В прошлую пятницу инвестиционная служба агентства Moo...
22.10.2018
China's economic expansion slowed to its weakest pace since the financial crisis, as top financial regulators launched an extraordinary coordinated effort to calm jittery investors. The rate of growth in the third quarter dropped to 6.5%, falling short of market expectations, official statistics...
22.10.2018
Спад на фондовом рынке по-прежнему сосредоточен в развитых экономиках. Индекс EuroStoxx 600 опустился на 0,42% под влиянием застоя в переговорах по Брекзиту и роста конфронтации между исполнительными органами ЕС и итальянской популист...
19.10.2018
Novartis AG said it would pay $2.1 billion for Endocyte Inc., a U.S. company developing a new treatment for prostate cancer, the Swiss pharmaceutical giant's latest move to double down on high-value prescription drugs. Endocyte specializes in so-called radiopharmaceuticals, a new class of drug...
19.10.2018
Как и ожидалось большинством участников рынка, протокол сентябрьского заседания Комитета открытого рынка ФРС оказался крайне скучным и не сообщил новой информации. Однако, судя по реакции рынков и особенно по ралли доллара, последовав...
18.10.2018
Carrefour SA (CA.FR) said Wednesday that third-quarter sales fell slightly, partly due to a depreciation of the Brazilian Real and the Argentine Peso. Sales in the quarter fell 2.8% to 21.09 billion euros ($24.42 billion) compared with the same period last year. Excluding currency effects, sales...
18.10.2018
 
Live chat